CAMBRIDGE, Mass., May 13, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting clinical data on its novel Hsp90 chaperone inhibitor, IPI-504, during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Fla. from May 29 through June 2, 2009.
The presentations for Infinity's Hsp90 chaperone inhibitor program are as follows:
Saturday, May 30, 2009: 8:00 a.m. - 12:00 p.m. EDT Poster Session Title: A phase 1b trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel Presenter: Gregory J. Riley, MD, PhD Location: Level 2, West Hall C, Poster Section G19 Saturday, May 30, 2009: 2:00 - 6:00 p.m. EDT Poster Session Title: A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory state IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status Presenter: Lecia V. Sequist, MD, MPH Location: Level 2, West Hall C, Poster Section P18
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.